India, July 23 -- Nuvectis Pharma, Inc. (NVCT), a clinical-stage biopharmaceutical company, announced on Thursday the receipt of marketing approval from the Chinese regulatory board, National Medicinal Products Administration (NMPA) for Ciprocopan in treating patients with Paroxysmal Nocturnal Hemoglobinuria.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder marked by the destruction of red blood cells, leading to anemia, fatigue, and an increased risk of blood clots and other complications.
NXP100 is an investigational, orally administered, once-daily small-molecule Factor B inhibitor designed to block the alternative complement pathway. The drug is being developed for complement-mediated diseases, including pa...